National Cancer Institute Selected Exact Sciences Lab and OncoExTra Test for ComboMATCH Clinical Trials
Portfolio Pulse from Benzinga Newsdesk
Exact Sciences Corp. (NASDAQ:EXAS) has been selected by the National Cancer Institute (NCI) to participate in the ComboMATCH clinical trials. The company's testing laboratory in Phoenix, AZ will use its new OncoExTra test to analyze tumor tissue and blood samples from patients, providing a comprehensive molecular picture of the patient's cancer and actionable results.
August 30, 2023 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Exact Sciences' selection by the NCI for the ComboMATCH clinical trials could potentially boost the company's reputation and increase demand for its OncoExTra test.
Exact Sciences' selection by the NCI for the ComboMATCH clinical trials is a significant endorsement of the company's capabilities and its OncoExTra test. This could potentially lead to increased demand for the test, boosting the company's revenues and positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100